- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors in liver cancer: which route to take?
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume 13, Issue 6, Pages 515-517
Publisher
Informa UK Limited
Online
2019-04-17
DOI
10.1080/17474124.2019.1605289
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer
- (2019) Jun Zhao et al. Expert Review of Gastroenterology & Hepatology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Discovering Synergistic Drug Combination from a Computational Perspective
- (2018) Pingjian Ding et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor SGI-110 in Hepatocellular Carcinoma
- (2018) Minmin Liu et al. HEPATOLOGY
- A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma
- (2018) R A Hlady et al. HEPATOLOGY
- Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
- (2018) Won Young Tak et al. INVESTIGATIONAL NEW DRUGS
- Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications
- (2018) Daniela Barros-Silva et al. Genes
- Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
- (2018) Yanrong Su et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
- (2016) Simone Jueliger et al. Epigenetics
- Epigenetics in liver disease: from biology to therapeutics
- (2016) Timothy Hardy et al. GUT
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- The molecular hallmarks of epigenetic control
- (2016) C. David Allis et al. NATURE REVIEWS GENETICS
- Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
- (2016) Pietro Di Fazio et al. Oncotarget
- Epigenetic polypharmacology: from combination therapy to multitargeted drugs
- (2016) Angel R. de Lera et al. Clinical Epigenetics
- Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis
- (2015) Hyung Seok Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells
- (2014) Roberta Montalbano et al. Translational Oncology
- The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines
- (2013) Alexander Henrici et al. MOLECULAR CARCINOGENESIS
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC
- (2011) Karl Quint et al. VIRCHOWS ARCHIV
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started